EX-99.1 2 ef20053399_ex99-1.htm PRESS RELEASE DATED AUGUST 7, 2025
Exhibit 99.1


FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports Second Quarter Revenue at High End of Guidance and Earnings Per Share Above Guidance

Company generates strong operating margin and cash position; narrows revenue and raises EPS guidance

PROVO, Utah — August 7, 2025 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter revenue at the high end of its guidance range and earnings per share exceeding guidance.

Executive Summary
Q2 2025 vs. Prior-year Quarter

Revenue
    
$386.1 million; (12.1)%
•       0.3% FX impact or $1.4 million
Earnings Per Share (EPS)
    
$0.43 compared to $(2.38) or $0.21 excluding impairment and other charges
Customers
    
771,407; (14)%
Paid Affiliates
    
130,799; (16)%
Sales Leaders
    
29,593; (23)%
 
“We are pleased with our solid performance in the second quarter including our efforts to drive revenue at the high end of our guidance and significantly exceeding our forecast for earnings per share,” said Ryan Napierski, Nu Skin president and CEO. “We are also pleased with our ongoing operational optimization efforts resulting in 8% operating margin despite top-line pressures on the business. Our Rhyz Manufacturing segment continues to perform well with 17% year-over-year revenue growth.
 
“We also made significant progress during the quarter in building sales leader engagement and alignment for our key initiatives for late 2025 and 2026. We are on schedule for a mid-Q4 limited preview of our Prysm iO intelligent wellness device, the next innovation in our line of the world’s best-selling beauty and wellness device systems.1 We believe this AI-powered wellness assessment device will stimulate growth in our nutritional supplements business by providing personalized product recommendations and subscriptions to drive customer lifetime value. Additionally, leveraging success principles for developing markets gleaned from Latin America, where we had 107% year-over-year revenue growth, we are on track with our plans for Q4 market pre-opening activities in India with a formal launch anticipated for mid-2026. We remain confident in our strategy going forward to return to growth and drive shareholder value.”

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 2
Q2 2025 Year-over-year Operating Results

Revenue
    
$386.1 million compared to $439.1 million
•       0.3% FX impact or $1.4 million
Gross Margin
    
68.8% compared to 70.0%
•       Nu Skin business was 77.5% compared to 76.1%
Selling Expenses
    
33.2% compared to 37.7%
•       Nu Skin business was 40.0% compared to 42.2%
G&A Expenses
    
27.6% compared to 26.9%
Operating Margin
    
8.0% compared to (28.6)% or 5.4% excluding impairment and other charges
Interest Expense
    
$2.5 million compared to $6.7 million
Other Income/ (Expense)
    
$(0.8) million compared to $0.6 million
Income Tax Rate
    
23.0% compared to 10.2% or 41.4% excluding impairment and other charges
EPS
    
$0.43 compared to $(2.38) or $0.21 excluding impairment and other charges

Stockholder Value

Dividend Payments
    
$3.0 million
Stock Repurchases
    
$0.0 million
•       $157.4 million remaining in authorization

Q3 and Full-year 2025 Outlook

Q3 2025 Revenue
    
$360 to $390 million; (16)% to (9)% or (13)% to (5)% excluding Mavely 2024 revenue
•       Approximately (1)% FX impact
Q3 2025 EPS
    
$0.25 to $0.35
2025 Revenue
    
$1.48 to $1.55 billion; (15)% to (11)% or (11)% to (7)% excluding Mavely 2024 revenue
•       Approximately (1)% FX impact
2025 EPS
    
$3.05 to $3.25 or $1.15 to $1.35 excluding Mavely gain and other charges

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 3
“We are encouraged by the positive results of our ongoing efforts to improve overall profitability, which has generated significant cash and further strengthened our balance sheet,” said James D. Thomas, chief financial officer. “Notably, we’ve achieved our goal of reaching a positive net cash position ahead of schedule, marking the first time in more than 4 years that we’ve been in such a position. Based on our first-half results and greater clarity into performance and consumer sentiment through the end of the year, we are narrowing our revenue and increasing our earnings guidance. For 2025, we project revenue of $1.48 billion to $1.55 billion and earnings per share of $3.05 to $3.25 with adjusted EPS of $1.15 to $1.35. For the third quarter, we project revenue between $360 million and $390 million, with earnings per share in the range of $0.25 to $0.35.”

Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 22, 2025.
 
About Nu Skin Enterprises Inc.

The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty and wellness device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
 
1Source Euromonitor International Limited; At-Home Beauty and Wellness Device Systems on a total retail level in RSP, excluding salon services that may offer packages, research conducted April – May 2024.
 
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 4
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the macro environment and the company’s performance, growth and growth opportunities, shareholder value, product previews and launches and their potential benefits to the business, investments, initiatives, and new market expansion and its timing; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “schedule,” “accelerate,” “project,” “remain,” “outlook,” “guidance,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve important risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

 •
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

•
economic conditions and events globally;

•
the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;

•
competitive pressures in the company’s markets;

•
risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;

•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

•
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;

•
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

•
uncertainties regarding the future financial performance of the businesses the company has acquired;

•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and

•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.
 
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
 
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 5
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share, operating margin and income tax rate, each excluding the gain from the Mavely sale, restructuring charges, impairment charges, unrealized investment loss, and/or other charges, as well as revenue growth rate excluding Mavely 2024 revenue, also are non-GAAP financial measures.


 •
Restructuring charges, impairment charges, and unrealized investment losses are not part of the ongoing operations of our underlying business;

•
Mavely revenue is no longer included in our operations following our sale of this business on January 2, 2025; and

•
the gain from the Mavely sale and the other charges incurred in connection with this sale that have been excluded in the non-GAAP financial measures are not typical for our ongoing operations.

The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, general & administrative expenses, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 6
The following table sets forth revenue for the three-month periods ended June 30, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):

   
Three Months Ended
June 30,
          
Constant-
Currency
  
   
2025
    
2024
    
Change
    
Change
  
Nu Skin
                        
Americas
  
$
72,946
    
$
84,935
      
(14.1
)%
    
(8.2
)%
Southeast Asia/Pacific
    
50,834
      
60,341
      
(15.8
)%
    
(17.3
)%
Mainland China
    
53,224
      
64,710
      
(17.7
)%
    
(18.0
)%
Japan
    
44,550
      
42,587
      
4.6
%
    
(3.1
)%
Europe & Africa
    
37,328
      
40,714
      
(8.3
)%
    
(13.0
)%
South Korea
    
34,068
      
44,119
      
(22.8
)%
    
(21.3
)%
Hong Kong/Taiwan
    
27,527
      
33,846
      
(18.7
)%
    
(21.1
)%
Nu Skin Other
    
427
      
(4
)
    
10,775.0
%
    
10,775.0
%
Total Nu Skin
    
320,904
      
371,248
      
(13.6
)%
    
(13.9
)%
Rhyz
                                
Manufacturing
    
60,400
      
51,473
      
17.3
%
    
17.3
%
Rhyz Other
    
4,834
      
16,360
      
(70.5
)%
    
(70.5
)%
Total Rhyz
    
65,234
      
67,833
      
(3.8
)%
    
(3.8
)%
Total
  
$
386,138
    
$
439,081
      
(12.1
)%
    
(12.4
)%

The following table sets forth revenue for the six-month periods ended June 30, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):

   
Six Months Ended
June 30,
          
Constant-
Currency
  
   
2025
    
2024
    
Change
    
Change
  
Nu Skin
                        
Americas
  
$
142,004
    
$
159,966
      
(11.2
)%
    
(5.0
)%
Southeast Asia/Pacific
    
103,006
      
120,406
      
(14.5
)%
    
(14.7
)%
Mainland China
    
100,999
      
125,777
      
(19.7
)%
    
(19.2
)%
Japan
    
87,315
      
86,823
      
0.6
%
    
(1.9
)%
Europe & Africa
    
70,349
      
82,987
      
(15.2
)%
    
(16.3
)%
South Korea
    
66,583
      
85,082
      
(21.7
)%
    
(17.4
)%
Hong Kong/Taiwan
    
55,974
      
64,312
      
(13.0
)%
    
(13.0
)%
Nu Skin Other
    
956
      
668
      
43.1
%
    
43.1
%
Total Nu Skin
    
627,186
      
726,021
      
(13.6
)%
    
(12.1
)%
Rhyz
                                
Manufacturing
    
115,690
      
101,775
      
13.7
%
    
13.7
%
Rhyz Other
    
7,752
      
28,591
      
(72.9
)%
    
(72.9
)%
Total Rhyz
    
123,442
      
130,366
      
(5.3
)%
    
(5.3
)%
Total
  
$
750,628
    
$
856,387
      
(12.3
)%
    
(11.1
)%

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 7
The following tables provide information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended June 30, 2025 and 2024.

   
Three Months Ended
June 30,
        
   
2025
    
2024
    
Change
  
Customers
                  
Americas
    
240,477
      
226,626
      
6
%
Southeast Asia/Pacific
    
72,814
      
88,662
      
(18
)%
Mainland China
    
117,325
      
179,021
      
(34
)%
Japan
    
105,961
      
109,357
      
(3
)%
Europe & Africa
    
126,146
      
143,336
      
(12
)%
South Korea
    
67,313
      
99,358
      
(32
)%
Hong Kong/Taiwan
    
41,371
      
47,154
      
(12
)%
Total Customers
    
771,407
      
893,514
      
(14
)%
Paid Affiliates
                        
Americas
    
28,827
      
29,531
      
(2
)%
Southeast Asia/Pacific
    
21,092
      
29,701
      
(29
)%
Mainland China
    
19,399
      
24,404
      
(21
)%
Japan
    
19,605
      
21,575
      
(9
)%
Europe & Africa
    
15,320
      
17,402
      
(12
)%
South Korea
    
16,986
      
22,116
      
(23
)%
Hong Kong/Taiwan
    
9,570
      
10,757
      
(11
)%
Total Paid Affiliates
    
130,799
      
155,486
      
(16
)%
Sales Leaders
                        
Americas
    
5,971
      
6,070
      
(2
)%
Southeast Asia/Pacific
    
4,126
      
5,601
      
(26
)%
Mainland China
    
5,790
      
10,266
      
(44
)%
Japan
    
5,882
      
6,116
      
(4
)%
Europe & Africa
    
2,695
      
3,432
      
(21
)%
South Korea
    
3,066
      
4,689
      
(35
)%
Hong Kong/Taiwan
    
2,063
      
2,418
      
(15
)%
Total Sales Leaders
    
29,593
      
38,592
      
(23
)%


●
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.


●
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.


●
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 8
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
   
2025
    
2024
    
2025
    
2024
  
Revenue
  
$
386,138
    
$
439,081
    
$
750,628
    
$
856,387
  
Cost of sales
    
120,405
      
131,904
      
237,934
      
255,146
  
Gross profit
    
265,733
      
307,177
      
512,694
      
601,241
  
                                 
Operating expenses:
                                
Selling expenses
    
128,228
      
165,463
      
246,774
      
319,005
  
General and administrative expenses
    
106,725
      
117,921
      
219,929
      
242,487
  
Restructuring and impairment expenses
    
—
      
149,350
      
25,114
      
156,484
  
Total operating expenses
    
234,953
      
432,734
      
491,817
      
717,976
  

                               
Operating income (loss)
    
30,780
      
(125,557
)
    
20,877
      
(116,735
)
Interest expense
    
2,526
      
6,720
      
5,809
      
14,045
  
Gain on sale of business
    
—
      
—
      
176,162
      
—
  
Other income (expense), net
    
(843
)
    
629
      
(29,218
)
    
233
  
                                 
Income (loss) before provision for income taxes
    
27,411
      
(131,648
)
    
162,012
      
(130,547
)
Provision (benefit) for income taxes
    
6,292
      
(13,390
)
    
33,378
      
(11,756
)
                                 
Net income (loss)
  
$
21,119
    
$
(118,258
)
  
$
128,634
    
$
(118,791
)
                                 
Net income (loss) per share:
                                
Basic
  
$
0.43
    
$
(2.38
)
  
$
2.59
    
$
(2.39
)
Diluted
  
$
0.43
    
$
(2.38
)
  
$
2.59
    
$
(2.39
)
                                 
Weighted-average common shares outstanding (000s):
                                
Basic
    
49,441
      
49,688
      
49,601
      
49,613
  
Diluted
    
49,499
      
49,688
      
49,748
      
49,613
  

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 9
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

   
June 30,
2025
    
December 31,
2024
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
264,159
    
$
186,883
  
Current investments
    
1,211
      
11,111
  
Accounts receivable, net
    
59,703
      
50,784
  
Inventories, net
    
180,377
      
190,242
  
Prepaid expenses and other
    
66,103
      
72,643
  
Current assets held for sale
    
—
      
26,936
  
Total current assets
    
571,553
      
538,599
  
                 
Property and equipment, net
    
374,207
      
379,595
  
Operating lease right-of-use assets
    
77,736
      
72,605
  
Goodwill
    
83,625
      
83,625
  
Other intangible assets, net
    
45,937
      
74,278
  
Other assets
    
290,635
      
298,008
  
Long-term assets held for sale
    
—
      
22,204
  
Total assets
  
$
1,443,693
    
$
1,468,914
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
28,734
    
$
34,880
  
Accrued expenses
    
220,172
      
217,808
  
Current portion of long-term debt
    
35,000
      
30,000
  
Current liabilities held for sale
    
—
      
13,919
  
Total current liabilities
    
283,906
      
296,607
  
                 
Operating lease liabilities
    
61,837
      
58,439
  
Long-term debt
    
213,900
      
363,613
  
Other liabilities
    
96,296
      
97,475
  
Long-term liabilities held for sale
    
—
      
1,325
  
Total liabilities
    
655,939
      
817,459
  
                 
Stockholders’ equity:
                
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
    
91
      
91
  
Additional paid-in capital
    
627,515
      
627,787
  
Treasury stock, at cost – 41.1 million and 40.8 million shares
    
(1,560,411
)
    
(1,563,614
)
Accumulated other comprehensive loss
    
(114,058
)
    
(124,758
)
Retained earnings
    
1,834,617
      
1,711,949
  
Total stockholders' equity
    
787,754
      
651,455
  
Total liabilities and stockholders’ equity
  
$
1,443,693
    
$
1,468,914
  

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 10
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
(in thousands, except for per share amounts)

   
Three months ended
June 30,
    
Six months ended
June 30,
  
   
2025
    
2024
    
2025
    
2024
  
Operating Income
  
$
30,780
    
$
(125,557
)
  
$
20,877
    
$
(116,735
)
Impact of other charges(1)
    
-
      
-
      
7,966
      
-
  
Impact of restructuring and impairment
    
-
      
149,350
      
25,114
      
156,484
  
Adjusted operating income
  
$
30,780
    
$
23,793
    
$
53,957
    
$
39,749
  
                                 
                                 
Operating margin
    
8.0
%
    
(28.6
)%
    
2.8
%
    
(13.6
)%
Operating margin, excluding certain charges
    
8.0
%
    
5.4
%
    
7.2
%
    
4.6
%
                                 
Revenue
  
$
386,138
    
$
439,081
    
$
750,628
    
$
856,387
  

(1) Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 11
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Mavely Gain and Certain Charges to GAAP Effective Tax Rate
(in thousands, except for per share amounts)

   
Three months ended
June 30,
    
Six months ended
June 30,
  
   
2025
    
2024
    
2025
    
2024
  
Provision (benefit) for income taxes
  
$
6,292
    
$
(13,390
)
  
$
33,378
    
$
(11,756
)
Impact of other charges(1) on provision for income taxes
    
-
      
-
      
725
      
-
  
Impact of restructuring and impairment on provision for income taxes
    
-
      
20,715
      
5,433
      
23,071
  
Impact of gain on Mavely sale on provision for income taxes
    
-
      
-
      
(31,104
)
    
-
  
Impact of unrealized investment loss on provision for income taxes
    
-
      
-
      
6,074
      
-
  
Provision for income taxes, excluding impact of Mavely gain and certain charges
  
$
6,292
    
$
7,325
    
$
14,506
    
$
11,315
  
                                 
Income before provision for income taxes
    
27,411
      
(131,648
)
    
162,012
      
(130,547
)
Impact of other charges(1)
    
-
      
-
      
7,966
          
Impact of restructuring and impairment expense:
    
-
      
149,350
      
25,114
      
156,484
  
Impact of gain on Mavely sale
    
-
      
-
      
(176,162
)
    
-
  
Impact of unrealized investment loss
    
-
      
-
      
28,077
      
-
  
Income before provision for income taxes, excluding impact certain charges
  
$
27,411
    
$
17,702
    
$
47,007
    
$
25,937
  
                                 
Effective tax rate
    
23.0
%
    
10.2
%
    
20.6
%
    
9.0
%
Effective tax rate, excluding impact of Mavely gain and certain charges
    
23.0
%
    
41.4
%
    
30.9
%
    
43.6
%

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 12
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)

   
Three months ended
June 30,
    
Six months ended
June 30,
  
   
2025
    
2024
    
2025
    
2024
  
Net income
  
$
21,119
    
$
(118,258
)
  
$
128,634
    
$
(118,791
)
Impact of other charges
                                
Other charges(1)
    
-
      
-
      
7,966
      
-
  
Tax impact
    
-
      
-
      
(725
)
    
-
  
Impact of restructuring and impairment expense:
                                
Restructuring and impairment
    
-
      
149,350
      
25,114
      
156,484
  
Tax impact
    
-
      
(20,715
)
    
(5,433
)
    
(23,071
)
Impact of gain on Mavely sale
                                
Gain on Mavely sale
    
-
      
-
      
(176,162
)
    
-
  
Tax impact
    
-
      
-
      
31,104
      
-
  
Impact of unrealized investment loss
                                
Unrealized investment loss
    
-
      
-
      
28,077
      
-
  
Tax impact
    
-
      
-
      
(6,074
)
    
-
  
Adjusted net income
  
$
21,119
    
$
10,377
    
$
32,501
    
$
14,622
  
                                 
                                 
Diluted earnings per share
  
$
0.43
    
$
(2.38
)
  
$
2.59
    
$
(2.39
)
Diluted earnings per share, excluding impact of Mavely gain and certain charges
  
$
0.43
    
$
0.21
    
$
0.65
    
$
0.29
  
                                 
Weighted-average common shares outstanding (000)
    
49,499
      
49,688
      
49,748
      
49,613
  

Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
page 13
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings Per Share

   
Year ended December 31, 2025
  
   
Low end
    
High end
  
Earnings Per Share
  
$
3.05
    
$
3.25
  
Impact of other charges
                
Other charges(1)
    
0.16
      
0.16
  
Tax impact
    
(0.01
)
    
(0.01
)
Impact of restructuring and impairment expense:
                
Restructuring and impairment
    
0.50
      
0.50
  
Tax impact
    
(0.11
)
    
(0.11
)
Impact of gain on Mavely sale
                
Gain on Mavely sale
    
(3.50
)
    
(3.50
)
Tax impact
    
0.62
      
0.62
  
Impact of unrealized investment loss
                
Unrealized investment loss
    
0.56
      
0.56
  
Tax impact
    
(0.12
)
    
(0.12
)
Adjusted EPS
  
$
1.15
    
$
1.35
  

NU SKIN ENTERPRISES, INC.
Reconciliation of Revenue Growth Rates Excluding Mavely to GAAP Revenue Growth Rates
(in thousands)

   
Three months ended
September 30, 2025
    
Year ended
December 31, 2025
  
   
Low end
    
High end
    
Low end
    
High end
  
2024 Revenue
  
$
430,145
    
$
430,145
    
$
1,732,084
    
$
1,732,084
  
Less: Mavely 2024 Revenue
    
18,391
      
18,391
      
69,620
      
69,620
  
Adjusted 2024 Revenue
  
$
411,754
    
$
411,754
    
$
1,662,464
    
$
1,662,464
  
                                 
Revenue Growth Rate
    
(16
)%
    
(9
)%
    
(15
)%
    
(11
)%
Revenue Growth Rate, excluding Mavely
    
(13
)%
    
(5
)%
    
(11
)%
    
(7
)%
                                 
2025 Forecasted Revenue
  
$
360,000
    
$
390,000
    
$
1,480,000
    
$
1,550,000
  

# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577